European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 284, P. 117200 - 117200
Published: Dec. 24, 2024
Language: Английский
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 13, 2025
The primary node molecules in the cell signaling network cancer tissues are maladjusted and mutated comparison to normal tissues, which promotes occurrence progression of cancer. Pancreatic (PC) is a highly fatal with increasing incidence low five-year survival rates. Currently, there several therapies that target networks PC. However, PC "cold tumor" unique immunosuppressive tumor microenvironment (poor effector T infiltration, antigen specificity), targeting single gene or pathway basically ineffective clinical practice. Targeted matrix therapy, targeted metabolic mutant vaccines, other emerging have shown great therapeutic potential, but results been disappointing. Therefore, we summarize identified potential drug-resistant aimed at overcoming barriers existing therapies.
Language: Английский
Citations
1
Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)
Published: Feb. 11, 2025
Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.
Language: Английский
Citations
1
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1868 - 1868
Published: Feb. 21, 2025
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway plays a crucial role in regulation autophagy, cellular mechanism vital for homeostasis through degradation damaged organelles and proteins. dysregulation this is significantly associated with cancer progression, metastasis, resistance to therapy. Targeting PI3K/AKT/mTOR signaling presents promising strategy treatment; however, traditional therapeutics frequently encounter issues related nonspecific distribution systemic toxicity. Nanoparticle-based drug delivery systems represent significant advancement addressing these limitations. Nanoparticles enhance bioavailability, stability, targeted therapeutic agents, facilitating precise modulation autophagy cells. Functionalized nanoparticles, such as liposomes, polymeric metal-based nanocarriers, facilitate tumor tissues, minimizing off-target effects improving efficacy. These can deliver multiple agents concurrently, enhancing PI3K/AKT/mTOR-mediated oncogenic pathways. This review examines advancements nanoparticle-mediated that pathway, emphasizing their contribution precision side integration nanotechnology molecularly therapies substantial potential resistance. Future initiatives must prioritize optimization clinical translation patient outcomes.
Language: Английский
Citations
1
Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 292 - 292
Published: March 10, 2025
Phosphoinositide 3-kinases (PI3Ks), members of the lipid kinase family, play a significant role in modulating immune cell functions, including activation, proliferation, and differentiation. Recent studies have identified PI3K signaling pathway as key regulator tumor biology microenvironment. This enhances activity regulatory T cells (Tregs) myeloid-derived suppressor (MDSCs), contributing to an immunosuppressive microenvironment that impairs effectiveness cancer vaccines immunotherapies. The present study explores isoforms, particularly p110γ p110δ, their associated pathways. therapeutic potential selective inhibitors capacity act synergistically with immunization strategies are analyzed. Targeting represents promising approach counteract tumor-induced suppression improve efficacy checkpoint vaccines, ultimately leading better clinical outcomes.
Language: Английский
Citations
1
Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149352 - 149352
Published: Feb. 1, 2025
Language: Английский
Citations
0
Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)
Published: Feb. 24, 2025
Abstract Epithelial ovarian cancer (EOC) is the second leading cause of death among women with gynecological cancers, particularly in high-income countries. Despite significant advancements molecular oncology and an initially positive response to primary chemotherapy, development drug resistance remains a major challenge effective management EOC. Consequently, there urgent need for innovative biological markers that can enable early diagnosis provide more accurate predictions recurrence risk patients. This study investigated expression profiles seven specific long noncoding RNAs (lncRNAs)—SNHG7, TUG1, XIST1, PRLB, TLR8-AS1, ZFAS1, PVT1—associated epithelial their relationship resistance. To achieve this, drug-resistant subtypes aggressive EOC cell lines, including carboplatin/paclitaxel-resistant OVCAR3 SKOV3 were developed. The selected lncRNAs quantitatively analyzed using RT-qPCR across various lines serum samples from 25 patients before six months after treatment, 23 healthy controls. findings revealed target significantly upregulated under conditions post-chemotherapy samples, suggesting involvement complex regulatory network. These results highlight critical roles progression treatment EOC, positioning them as potential therapeutic targets biomarkers stratification. Identifying reliable lncRNA could detection at developing resistance, thereby facilitating personalized strategies improve patient outcomes survival rates.
Language: Английский
Citations
0
The Analyst, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Drug-mediated protein–protein interaction and drug–protein form the basis of drug development pharmacological research.
Language: Английский
Citations
0
Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149467 - 149467
Published: April 1, 2025
Language: Английский
Citations
0
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 22, 2025
Language: Английский
Citations
0
Antioxidants and Redox Signaling, Journal Year: 2024, Volume and Issue: 41(13-15), P. 957 - 975
Published: July 6, 2024
Both redox and pH are important regulatory processes that underpin cell physiological functions, in addition to influencing cancer development tumor progression. The thioredoxin (Trx) glutathione systems the carbonic anhydrase (CA) proteins considered key regulators of cellular pH, respectively, with components Trx system CAs regarded as therapeutic targets. However, axis cells is an underexplored topic research.
Language: Английский
Citations
2